-
公开(公告)号：US20220106281A1
公开(公告)日：2022-04-07
申请号：US17108416
申请日：2020-12-01
发明人： Carmela Sidrauski , Marina Pliushchev , Jennifer M. Frost , Lawrence A. Black , Xiangdong Xu , Ramzi Farah Sweis , Lei Shi , Qingwei Zhang , Yunsong Tong , Charles W. Hutchins , SeungWon Chung , Michael J. Dart
IPC分类号： C07D307/82 , C07D213/74 , C07D231/14 , C07D237/10 , C07D241/12 , C07D241/44 , C07D261/08 , C07D277/32 , C07D213/57 , C07D307/56 , C07C233/74 , C07D213/54 , C07C235/54 , C07C233/79 , C07C255/41 , C07C255/57 , C07C235/14
摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
-
公开(公告)号：US20190194135A1
公开(公告)日：2019-06-27
申请号：US16098946
申请日：2017-05-05
发明人： Carmela Sidrauski , Marina Pliushchev , Jennifer M. Frost , Lawrence A. Black , Xiangdong Xu , Ramzi Farah Sweis , Lei Shi , Qingwei I. Zhang , Yunsong Tong , Charles W. Hutchins , Seungwon Chung , Michael J. Dart
IPC分类号： C07D213/42 , C07D261/08 , C07D231/12 , C07D241/12 , C07D213/89 , C07D271/10 , C07D307/36 , C07D277/28 , C07D471/04 , C07D333/20 , C07D209/14 , A61K31/44 , A61K31/42 , A61K31/415 , A61K31/4965 , A61K31/4245 , A61K31/341 , A61K31/426 , A61K31/4439 , A61K31/381 , A61K31/4045 , C07D263/32 , A61K31/421 , C07D235/00 , A61K31/417 , C07D239/34 , A61K31/505 , C07D237/08 , A61K31/50 , C07C235/22 , A61K31/197 , C07C311/16 , A61K31/18 , C07C323/09
CPC分类号： C07D213/42 , A61K31/18 , A61K31/197 , A61K31/341 , A61K31/381 , A61K31/4045 , A61K31/415 , A61K31/417 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/44 , A61K31/4439 , A61K31/4965 , A61K31/50 , A61K31/505 , C07C235/22 , C07C311/16 , C07C323/09 , C07C2602/38 , C07C2602/40 , C07C2602/42 , C07C2602/44 , C07C2603/90 , C07D209/14 , C07D213/40 , C07D213/64 , C07D213/89 , C07D231/12 , C07D235/00 , C07D237/08 , C07D239/34 , C07D241/12 , C07D261/08 , C07D263/32 , C07D271/07 , C07D271/10 , C07D277/28 , C07D307/36 , C07D307/52 , C07D333/20 , C07D471/04
摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
-
公开(公告)号：US20190135772A1
公开(公告)日：2019-05-09
申请号：US16098679
申请日：2017-05-05
发明人： Carmela Sidrauski , Marina Pliushchev , Jennifer M. Frost , Lawrence A. Black , Xiangdong Xu , Ramzi Farah Sweis , Lei Shi , Qingwei I. Zhang , Yunsong Tong , Charles W. Hutchins , Seungwon Chung , Michael J. Dart
IPC分类号： C07D307/82 , C07D307/56 , C07D277/32 , C07D261/08 , C07D241/44 , C07D241/12 , C07D237/10 , C07D231/14 , C07D213/74 , C07D213/57
摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
-
公开(公告)号：US20190015402A1
公开(公告)日：2019-01-17
申请号：US16042447
申请日：2018-07-23
申请人： AbbVie Inc.
发明人： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC分类号： A61K31/454 , A61K31/4418 , C07D401/14 , A61K45/06 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K31/435 , A61K31/4184 , A61K31/422 , A61K31/4355 , A61K31/438 , A61K31/4178 , C07F7/02 , C07D491/113 , C07D453/00 , C07D417/14 , C07D413/14 , C07D405/14 , C07D403/14 , A61K31/4439
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US10039754B2
公开(公告)日：2018-08-07
申请号：US15431069
申请日：2017-02-13
申请人： AbbVie Inc.
发明人： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC分类号： A61K38/00 , A61K31/454 , A61K45/06 , A61K31/4184 , A61K31/4439 , A61K31/422 , A61K31/438 , A61K31/4545 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/4418 , A61K31/5377 , A61K31/4355 , A61K31/4178
CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US09840495B2
公开(公告)日：2017-12-12
申请号：US15106670
申请日：2014-12-19
发明人： Hervé Geneste , Wilfried Hornberger , Charles W. Hutchins , Katja Jantos , Andreas Kling , Loic Laplanche , Marcel Van Gaalen
IPC分类号： A01N43/00 , A61K31/00 , C07D401/14 , C07D401/04 , C07B59/00 , C07D405/14 , C07D491/107
CPC分类号： C07D401/14 , C07B59/002 , C07B2200/05 , C07D401/04 , C07D405/14 , C07D491/107
摘要： The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
-
公开(公告)号：US09527811B2
公开(公告)日：2016-12-27
申请号：US14570996
申请日：2014-12-15
发明人： Helmut Mack , Andreas Kling , Katja Jantos , Achim Moeller , Wilfried Hornberger , Charles W. Hutchins
IPC分类号： C07D207/26 , C07D207/28 , C07D401/12 , C07D233/34 , C07D239/10 , C07D207/22 , C07D211/78 , C07D211/76 , C07D233/32 , C07D275/03 , C07D401/06 , C07D405/12 , C07D409/12 , C07D417/12 , C07D213/81
CPC分类号： C07D207/22 , C07D207/26 , C07D207/28 , C07D211/76 , C07D211/78 , C07D213/81 , C07D233/32 , C07D233/34 , C07D239/10 , C07D275/03 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or 2H-atoms replaced with identical or different radicals Ry, wherein Ry and Ry# have the meanings mentioned in the claims.
-
公开(公告)号：US20210074147A1
公开(公告)日：2021-03-11
申请号：US16828351
申请日：2020-03-24
申请人： AbbVie Inc.
发明人： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
摘要： The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号：US20170157104A1
公开(公告)日：2017-06-08
申请号：US15431069
申请日：2017-02-13
申请人： AbbVie Inc.
发明人： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC分类号： A61K31/454 , A61K31/4184 , A61K31/4439 , A61K31/422 , A61K31/438 , A61K31/4178 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/4418 , A61K31/5377 , A61K31/4355 , A61K45/06 , A61K31/4545
CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
10.发明授权公开(公告)号：US09650334B2
公开(公告)日：2017-05-16
申请号：US14215533
申请日：2014-03-17
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC分类号： A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC分类号： C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
摘要： The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.076 秒)
